"Our first collaboration is with Novartis for use of TPE with a product marketed by Novartis and for use with certain other related Novartis products in development."
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's TPE technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
The Company has successfully demonstrated proof-of-principle in delivering small proteins, peptides, saccharides and heretofore-insoluble small molecules via the oral route.
Chiasma is backed by ARCH Venture Partners, MPM Capital, F2 Ventures, 7 Health Ventures and the MPM Novartis Strategic Fund.
The Company's Chairman & CEO is Fredric Price, formerly Chairman of Omrix Biopharmaceuticals and Chairman & CEO of BioMarin Pharmaceutical; he is located in New York. The company's Chief Operating Officer is Roni Mamluk, PhD, formerly head of preclinical at Adnexus Therapeutics. She led the discovery of the TPE technology and currently is headi
|SOURCE Chiasma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved